Dr Peter Mutch
ICON Drug Development Services
Peter Mutch graduated from Imperial College London with a BSc (Hons) in Biochemistry. He is Director, Preclinical Development, at ICON plc and is responsible for providing expert DMPK input into client drug projects. Peter started his career working in drug metabolism at the CRO Inveresk Research, and moved to GSK (then Glaxo) in 1991. In his early career at Glaxo, Peter worked mainly on the drug metabolism of development compounds, across a number of therapeutic areas including gastrointestinal and HIV. He later moved to a position in Discovery DMPK, developing DMPK lead optimization strategies for respiratory and inflammatory disease targets. He also had responsibility for leading a multi-disciplinary team of DMPK staff. He was a member of due diligence teams appraising potential in-license opportunities and co-led an international, cross-functional inhaled drug discovery project. Moving to AstraZeneca R&D in 2006, he latterly provided expert non-compartmental pharmacokinetic input into early phase clinical studies. Other responsibilities during his time at AstraZeneca included outsourcing responsibility for ADME, bioanalytical and biomarker studies, leading a biotransformations team, and acting as DMPK representative on cross-functional product development teams. He joined Aptiv Solutions (later acquired by ICON) in 2011.